Skip to content
Screener

BridgeBio Pharma BBIO Debt-to-equity

Discontinued — last reported Q4 '20

Debt-to-equity at other companies

Pfizer logo
PfizerPFE
0.7×0.0×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.6×-0.7×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
0.7×+0.6×
ALN
Alnylam PharmaceuticalsALNY
0.2×-0.9×
Celcuity logo
CelcuityCELC
2.6×+1.4×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
0.1×0.0×

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Current ratio1.5×-3.0×

Where this comes from

Calculated from BridgeBio Pharma’s reported figures.

total debt/total stockholders equity=2×

Based on the most recent quarter.

The source filing: BridgeBio Pharma’s 10-K, filed February 23, 2023. Open the filing →

Filed
Feb 23, 2023
Fiscal year
FY2022
Accession
0000950170-23-004145

FAQ

What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.